cyclohexanol has been researched along with Parkinson Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aerts, JMFG; Artola, M; Futerman, AH; Kallemeijn, WW; Kuo, CL; Lelieveld, LT; Meijer, AH; Mirzaian, M; Overkleeft, HS; Spaink, HP; Vardi, A; Zoutendijk, I | 1 |
| Fauser, M; Haehner, A; Hummel, T; Klingelhoefer, L; Reichmann, H; Storch, A; Tosch, C; Wolz, M | 1 |
| Auinger, P; Christine, CW; Factor, SA; Juncos, J; Leentjens, AF; Lyness, JM; Marsh, L; McDonald, W; Moonen, AJ; Panisset, M; Pfeiffer, R; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J; Wijers, A | 1 |
| Abeynaike, L; Rajapakse, S; Wickramarathne, T | 1 |
| Fernández-Ruiz, J; García, C; García-Arencibia, M; Palomo-Garo, C; Pertwee, R; Ramos, J | 1 |
| Ardashov, OV; Il'ina, IV; Karpova, EV; Korchagina, DV; Morozova, EA; Pavlova, AV; Salakhutdinov, NF; Tolstikova, TG; Volcho, KP | 1 |
| Friedman, JH; Weintraub, D | 1 |
| Black, KJ; Brodsky, M; Christine, CW; Como, PG; Elmer, L; Factor, SA; Fernandez, HH; Horn, S; Hyson, HC; Jiang, W; Juncos, J; Kurlan, R; Lyness, JM; Manning, C; Marsh, L; McDermott, MP; McDonald, W; Panisset, M; Pearson, N; Pfeiffer, R; Press, D; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J | 1 |
| Ardashov, OV; Korchagina, DV; Pavlova, AV; Salakhutdinov, NF; Tolstikova, Ty; Volcho, KP | 1 |
| Cunningham, LA | 1 |
| Khen, S; Patrick, RL; Patrick, SL; Sañudo-Peña, MC; Tsou, K; Walker, JM | 1 |
| Akyol, A; Bolukbasi, O | 1 |
1 review(s) available for cyclohexanol and Parkinson Disease
| Article | Year |
|---|---|
Depression in the medically ill: choosing an antidepressant.
Topics: Antidepressive Agents; Cerebrovascular Disorders; Clinical Trials as Topic; Comorbidity; Cyclohexanols; Decision Making; Dementia; Depressive Disorder; Humans; Neoplasms; Parkinson Disease; Prevalence; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1994 |
2 trial(s) available for cyclohexanol and Parkinson Disease
| Article | Year |
|---|---|
Olfactory training in patients with Parkinson's disease.
Topics: Acyclic Monoterpenes; Adult; Aged; Aldehydes; Cyclohexanols; Discrimination, Psychological; Eucalyptol; Eugenol; Female; Humans; Male; Middle Aged; Monoterpenes; Olfactory Perception; Parkinson Disease; Sensory Thresholds | 2013 |
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Parkinson Disease; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2012 |
9 other study(ies) available for cyclohexanol and Parkinson Disease
| Article | Year |
|---|---|
In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
Topics: Animals; beta-Glucosidase; Brain; Cyclohexanols; Disease Models, Animal; Enzyme Assays; Glucosylceramidase; Glycoside Hydrolase Inhibitors; HEK293 Cells; Humans; Inositol; Isoenzymes; Kinetics; Larva; Lysosomes; Mice; Parkinson Disease; Zebrafish | 2019 |
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.
Topics: Aged; Antidepressive Agents; Anxiety; Cyclohexanols; Datasets as Topic; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Venlafaxine Hydrochloride | 2014 |
Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease.
Topics: Acute Kidney Injury; Adult; Cyclohexanols; Humans; Male; Parkinson Disease; Rhabdomyolysis; Serotonin Syndrome; Venlafaxine Hydrochloride | 2010 |
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
Topics: Animals; Antioxidants; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dopamine; Dronabinol; Glutamic Acid; Lipopolysaccharides; Male; Mice; Motor Activity; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Haloperidol; Levodopa; Mice; Mice, Inbred C57BL; Molecular Conformation; Motor Activity; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Neurotransmitter; Stereoisomerism | 2011 |
Glad about SAD (PD).
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Parkinson Disease; Paroxetine; Venlafaxine Hydrochloride | 2012 |
3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the importance of functional groups for antiparkinsonian activity.
Topics: Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Molecular Conformation; Parkinson Disease | 2013 |
Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Cannabinoids; Corpus Striatum; Cyclohexanols; Globus Pallidus; Injections, Intraventricular; Male; Motor Activity; Neural Pathways; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1998 |
Spontaneous erections and libido increase associated with venlafaxine.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Humans; Libido; Male; Middle Aged; Parkinson Disease; Penile Erection; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 1999 |